Numab Therapeutics has started clinical trials on its first proprietary cancer antibody test. The international study is initially aiming to determine the optimal dosing for various cancer indications. Thereafter anti-tumor activity will be tested on certain tumors.

The oncology-focused biopharmaceutical company Numab Therapeutics is “writing the next chapter in cancer immunotherapy”, according to the company’s self-description. Numab manufactures multi-specific anti-bodies that open up new therapeutic opportunities. The clinical phase has now been started for the company’s most important drug candidate, the lead molecule NM21-1480, according to a press release.

This international, multi-centric Phase 1/2 clinical study will initially enroll up to 102 cancer patients at four major clinical centers across North America and Taiwan. Over time, additional hospitals will be included in the study. In this first study phase, the investigation will be centered on the safety and tolerability of increasing doses in patients with various forms of solid tumors with the aim of determining a recommended dose. After this, the anti-tumor activity of the compound will be explored in patients suffering from selected tumor types.

“Advancing NM21-1480 into clinical trials is an exciting and transformative step for Numab Therapeutics,” comments Founder and CEO, David Urech. “Our team has immense faith in the capability of NM21-1480 to invigorate anticancer immunity. The unique properties of this molecule are exemplary for our mission to deliver the highest quality of immuno-oncology drugs aiming at better patient outcomes.”

NM21-1480 represents a next-generation checkpoint modulator. Immune checkpoints are receptors that either reduce or increase, in other words modulate, the body’s immune response. The mechanism of action of the Numab modulator, which is now being tested, and its preclinical data suggest that it will be able to overcome several limitations associated with the current standard of therapy using checkpoint modulators.

Life Sciences

Do you want to be close to major players, innovative start-ups and leading research institutes in the life sciences space? Then the Greater Zurich Area is the right choice for you. The region has evolved into a dynamically expanding life sciences hotspot. The secret of success? Academic excellence, business-friendly regulations, IP protection, a large international talent pool and R&D collaborations between universities and start-ups as well as large multinational corporations (like Roche, Johnson & Johnson, Biogen or Stryker) serve as an engine motor for innovation. Learn more about the pharmaceutical, biotechnology and medical technology sector in the Greater Zurich Area.

Meet with an expansion expert

Our services are free of charge and include:

  • Introduction to key contacts in industry, academia, and government
  • Advice on regulatory framework, taxes, labor, market, and setting up a company
  • Custom-made fact-finding visits, including office and co-working space